Allogeneic transplantation provides added benefit to FMS‐like tyrosine kinase 3 (FLT3) inhibitors for both low‐intensity and high‐intensity regimens in FLT3‐mutated acute myeloid leukemia

Documenti analoghi

• A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukemia
  di: Alexandre Bazinet, et al.
  Pubblicazione: (2025)
• Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3‐tyrosine kinase domain mutations: Prognostic implications of NPM1 co‐mutation
  di: Sankalp Arora, et al.
  Pubblicazione: (2025)
• Maintenance therapy with the FMS‐like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS‐like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study
  di: Emmanuel Gyan, et al.
  Pubblicazione: (2025)
• Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax‐based therapy
  di: Guangyang Weng, et al.
  Pubblicazione: (2024)
• Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting
  di: Jacopo Nanni, et al.
  Pubblicazione: (2025)